Selecta Biosciences, Inc.
Records under this name other than the patents Selecta Biosciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.
Back to Selecta Biosciences, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,235,057 | Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,508,249 | Methods Related to Administering Immunosuppressants and Non-Allergenic Antigens to Reduce or Prevent Anaphylaxis Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,472,167 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,194,078 | Methods and Compositions Related to Combined Treatment with Anti-Inflammatories and Synthetic Nanocarriers Comprising an Immunosuppressant Formerly held In force · High confidence | In force | High confidence | |
| US 10,071,114 | Methods and Compositions for Attenuating Gene Expression Modulating Anti-Viral Transfer Vector Immune Responses Lapsed on the fee record Ended Sep 11, 2026 · Medium confidence | Lapsed on the fee record | Ended Sep 11, 2026 | Medium confidence |
| US 10,046,064 | Methods and Compositions for Attenuating Exon Skipping Anti-Viral Transfer Vector Immune Responses Lapsed on the fee record Ended Aug 14, 2026 · Medium confidence | Lapsed on the fee record | Ended Aug 14, 2026 | Medium confidence |
| US 9,987,354 | Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells Lapsed on the fee record Ended Jun 5, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 5, 2026 | From the USPTO record |
| US 10,441,651 | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Lapsed on the fee record Ended Oct 15, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 15, 2023 | From the USPTO record |
| US 9,066,978 | Dose selection of adjuvanted synthetic nanocarriers Lapsed on the fee record Ended Jun 30, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jun 30, 2023 | From the USPTO record |
| US 9,006,254 | Immunomodulatory agent-polymeric compounds Lapsed on the fee record Ended Apr 14, 2023 · From the USPTO record | Lapsed on the fee record | Ended Apr 14, 2023 | From the USPTO record |